Clinical trials
Locally Advanced Oral Squamous Cell Carcinoma clinical trials
Below are recruiting locally advanced oral squamous cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 212 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05969171RecruitingPhase 2
Surufatinib plus chemotherapy for advanced pancreatic cancer
This Phase 2 study tests whether adding surufatinib to first-line treatment (either AG or a similar AG-based regimen) can improve outcomes for people with locally advanced or metastatic pancreatic cancer. You may be considered if your cancer cannot be removed by surgery and you’ve already had a short course of similar treatment with a response.
ShanghaiAges 18–75 - NCT05136326RecruitingPhase 2
Pre-surgery chemo-radiation for rectal cancer without MGMT
This trial studies whether adding two chemotherapy medicines (capecitabine and temozolomide) to standard pre-surgery chemo-radiation can work better for people with locally advanced rectal cancer that has a specific tumor marker pattern (MGMT “silenced”) and is mismatch-repair proficient (MSS). It aims to shrink the tumor before surgery and improve cancer control.
MilanAges 18 years+ - NCT05262491RecruitingPhase 1
Early drug study for advanced GI or solid cancers that failed treatment
This Phase 1 trial tests BL-B01D1, a new cancer medicine, in people with advanced or metastatic gastrointestinal or other solid tumors that did not respond to standard treatment (or cannot use standard treatment). It also looks at whether a tumor marker called TROP2 may help predict who benefits.
Beijing, Beijing MunicipalityAges 18–75 - NCT05628922RecruitingPhase 2
Blood EBV DNA–guided therapy for advanced nasopharyngeal cancer
This trial tests a treatment approach for people with locally advanced nasopharyngeal cancer using their blood EBV DNA level (a cancer-related virus marker). It may help doctors choose and adjust therapy based on how much of this marker is in your blood after standard treatment.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05758389RecruitingPhase 2
Immunotherapy plus chemo for locally advanced head and neck cancer
This Phase 2 study tests whether tislelizumab (an immunotherapy) combined with chemotherapy works better for locally advanced head and neck squamous cell cancer. It aims to improve cancer control when the tumor is large and has not spread to distant organs.
Nanjing, JiangsuAges 18–75 - NCT05817903RecruitingPhase 2
Nivolumab with or without axitinib after prior nivolumab
This Phase 2 trial studies whether adding axitinib to nivolumab (or giving nivolumab alone) can better control advanced clear-cell kidney cancer after standard initial treatment with nivolumab plus ipilimumab. It may help by extending response or slowing tumor growth while improving how long treatment works.
BresciaAges 18 years+ - NCT05957016RecruitingPhase 2
New treatment before and during rectal radiation with chemo
This Phase 2 study tests a treatment plan given before surgery (neoadjuvant) along with radiation and chemotherapy (concurrent chemoradiotherapy) for locally advanced rectal cancer. It may help shrink the cancer before the next steps of care and improve control of the disease.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06021626RecruitingPhase 1
Study of CRD3874-SI for advanced solid tumors
This trial tests a new drug called CRD3874-SI for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and can shrink tumors.
Basking Ridge, New JerseyAges 18 years+ - NCT06042894RecruitingPhase 2
Study of two drugs for advanced HER2-negative breast cancer
This trial tests two experimental drugs, SI-B003 and BL-B01D1 plus SI-B003, for people with HER2-negative breast cancer that has spread or cannot be removed by surgery. It is for those who have tried standard treatments or cannot have them.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06204991RecruitingPhase 1
T-cell therapy for advanced melanoma
This trial tests a new treatment called ADP-TILIL7 for people with advanced melanoma. It uses your own immune cells (T-cells) that are taken from a tumor, multiplied in a lab, and then given back to you to fight the cancer. The goal is to see if this treatment is safe and works better than standard options.
HerlevAges 18–75 - NCT06405139RecruitingPhase 2
Chemo combo (nanoliposomal irinotecan, oxaliplatin, capecitabine) before surgery for locally advanced colorectal cancer
This trial tests a combination of three chemotherapy drugs (nanoliposomal irinotecan, oxaliplatin, and capecitabine) given before surgery to shrink locally advanced colorectal cancer that cannot be treated with radiation. The goal is to make the tumor removable with a better chance of complete removal (R0 resection).
BeijingAges 18–70 - NCT06770270RecruitingPhase 2
Immunotherapy with radiation and chemo before rectal cancer surgery
This trial tests adding an immunotherapy drug (pucotenlimab) to standard radiation and chemotherapy before surgery for locally advanced rectal cancer. The goal is to see if this combination can shrink the tumor more effectively and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT06826079RecruitingPhase 2/Phase 3
Sorbitol plus chemo and immunotherapy for advanced gastric cancer
This trial tests adding sorbitol to standard chemotherapy and an immunotherapy drug (tirellizumab) for people with locally advanced stomach cancer. The goal is to see if this combination is safe and helps shrink tumors before surgery.
Wuhan, HubeiAges 18–70 - NCT06895447RecruitingPhase 2
Robot-assisted stomach cancer surgery after chemo or radiation
This trial tests whether using a robotic arm to remove stomach cancer is safe and effective for patients who have already received chemotherapy or radiation. If you have stage III stomach cancer and are healthy enough for surgery, this approach may offer a more precise operation.
Nanjing, JiangsuAges 18–80 - NCT06927986RecruitingPhase 3
Testing SYS6010 vs chemo for advanced EGFR-mutated lung cancer
This trial tests a new drug called SYS6010 compared to standard chemotherapy for people with EGFR-mutated lung cancer that has stopped responding to pill treatments. It may offer a new option if your current EGFR TKI is no longer working.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07042685RecruitingPhase 2
5-FU and Fruquintinib for advanced colorectal cancer
This trial tests a combination of two drugs (5-FU and fruquintinib) in people with advanced colorectal cancer that cannot be removed by surgery or has spread. It is for those who have not had chemotherapy before.
Houston, TexasAges 18 years+ - NCT07279077RecruitingPhase 2
Low-dose radiation with chemo and immunotherapy for high-risk colon cancer
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (PD-1 inhibitor) for people with a specific type of high-risk colon cancer that has not spread. The goal is to see if this approach can shrink the tumor before surgery and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07389876Recruiting
Second-line treatment for advanced stomach cancer with nab-paclitaxel
This trial tests a new chemotherapy combination for patients with advanced stomach cancer that has worsened after initial treatment. It aims to find a better second-line option using a drug called nab-paclitaxel.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07478731RecruitingPhase 2
Combination therapy for advanced rectal cancer before surgery
This trial tests a new drug called SHR-1701 combined with standard chemotherapy and radiation for people with locally advanced rectal cancer. The goal is to shrink the tumor before surgery, making it easier to remove completely.
Wuhan, HubeiAges 18–75 - NCT04090567RecruitingPhase 2
Olaparib with two partners for advanced BRCA breast cancer
This trial tests whether the drug olaparib works better when combined with cediranib or AZD6738 in people with advanced or metastatic BRCA (inherited) breast cancer. It may help shrink tumors or slow cancer growth after prior treatment with a PARP inhibitor.
Houston, TexasAges 18 years+ - NCT06805617RecruitingPhase 2
Ivonescimab for advanced salivary gland cancer
This trial tests a new drug called Ivonescimab for people with advanced salivary gland cancer that has spread or cannot be removed surgically. The goal is to see if the drug can shrink tumors or slow cancer growth.
Boston, MassachusettsAges 18 years+ - NCT07314216RecruitingPhase 2
Firmonertinib plus radiation for stage III lung cancer with rare EGFR mutations
This trial tests whether combining the targeted pill firmonertinib with radiation therapy can help people with stage III non-small cell lung cancer that has certain rare EGFR mutations. It is for those whose cancer cannot be removed by surgery.
Changsha, HunanAges 18 years+ - NCT05394831RecruitingPhase 1/Phase 2
Study of an EGFR-targeted drug for advanced lung cancer
This trial tests a new drug (JIN-A02) in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has specific EGFR mutations. It mainly checks whether the treatment is safe and tolerable, and how the body handles the drug, with possible benefit depending on your mutation type.
Orange, CaliforniaAges 18 years+ - NCT05937906RecruitingPhase 1/Phase 2
Chemo and immunotherapy plus short targeted drug for lung cancer
This Phase 1/2 trial tests how safe and how well a combination of chemo and immunotherapy works when followed by a short course of a targeted “MEK” inhibitor as first treatment for metastatic lung adenocarcinoma with PD-L1 below 50%. It may help some people control cancer better, while also providing more information about side effects and the best way to use these medicines together.
Dijon, BurgundyAges 18 years+
Hear when a new Locally Advanced Oral Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced oral squamous cell carcinoma?
- Yes. Clin2 currently lists 212 recruiting locally advanced oral squamous cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced oral squamous cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced oral squamous cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Locally Advanced Esophageal Squamous Cell Carcinoma
- Locally Recurrent Oral Cavity Squamous Cell Carcinoma
- Oral Squamous Cell Carcinoma
- Oral Cavity Squamous Cell Carcinoma
- Advanced Clear Cell Renal Cell Carcinoma
- Advanced Esophageal Squamous Cell Carcinoma
- Recurrent Oral Cavity Squamous Cell Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.